ROQ — Roquefort Therapeutics Share Price
Last trade - 00:00- £2.87m
- £2.87m
- £0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.7 | ||
| Price to Tang. Book | 0.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3,982.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.02% | ||
| Return on Equity | -22.47% | ||
| Operating Margin | -127420.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | 0 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Company’s portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- January 1st, 1970
- Incorporated
- August 17th, 2020
- Public Since
- March 22nd, 2021
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
- London Stock Exchange
- Shares in Issue
- 154,977,483
- Address
- 85 Great Portland Street,, First Floor, LONDON, W1W 7LT
- Web
- https://www.roquefortplc.com/
- Phone
- +44 2039188633
- Auditors
- Jeffreys Henry Audit Limited
Latest News for ROQ
Upcoming Events for ROQ
Roquefort Therapeutics PLC Annual Shareholders Meeting
Half Year 2025 Roquefort Therapeutics PLC Earnings Release
Similar to ROQ
3i
London Stock Exchange
450
London Stock Exchange
Aberdeen
London Stock Exchange
Achilles Investment Co
London Stock Exchange
Agronomics
London Stock Exchange
FAQ
As of Today at 22:59 UTC, shares in Roquefort Therapeutics are trading at 1.85p. This share price information is delayed by 15 minutes.
Shares in Roquefort Therapeutics last closed at 1.85p and the price had moved by -59.34% over the past 365 days. In terms of relative price strength the Roquefort Therapeutics share price has underperformed the FTSE All Share Index by -60.46% over the past year.
There is no consensus recommendation for this security.
Find out moreRoquefort Therapeutics does not currently pay a dividend.
Roquefort Therapeutics does not currently pay a dividend.
Roquefort Therapeutics does not currently pay a dividend.
To buy shares in Roquefort Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1.85p, shares in Roquefort Therapeutics had a market capitalisation of £2.87m.
Here are the trading details for Roquefort Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ROQ
Based on an overall assessment of its quality, value and momentum Roquefort Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Roquefort Therapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -53.39%.
As of the last closing price of 1.85p, shares in Roquefort Therapeutics were trading -46.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Roquefort Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1.85p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Roquefort Therapeutics' directors